Sunil Rangarajan, MD

Sunil Rangarajan, MD, is a board-certified medical oncologist who offers comprehensive care for all cancers. He completed training in the Physician-Scientist pathway at the University of Alabama at Birmingham after completing a unique dual fellowship in oncology and nephrology. Dr. Rangarajan was awarded the 2020 Conquer Cancer Foundation of the American Society of Clinical Oncology – Young Investigator Award for his work on identifying novel biomarkers of renal dysfunction in patients with multiple myeloma. Away from work, he enjoys playing chess, nature photography and traveling.

• MultiCare Oncology Group

• American Association for Cancer Research
• American Journal of Clinical Oncology - Peer Reviewer
• American Society of Clinical Oncology
• American Society of Hematology
• Clinical and Translational Oncology Journal - Peer Reviewer
• International Journal of Gastrointestinal Cancer - Peer Reviewer
• Leukemia Research and Nutrition Journal - Editorial Board Member

• Acute kidney injury in patients treated with immune checkpoint inhibitors.
  Journal for ImmunoTherapy of Cancer 2021;9:e003467. DOI: 10.1136/JITC-2021-003467
• Clinical Features and Outcomes of Immune Checkpoint Inhibitor-associated AKI: a multicenter study. JASN February 2020, 31 (2) 435-446; DOI: 10.1681/ASN.2019070676
• Heparanase-enhanced shedding of syndecan-1 and its role in driving disease pathogenesis and progression. 
  Journal of Histochemistry and Cytochemistry. July 2020
• Sinister small extracellular vesicles that support tumor survival and progression. 
  18 August 2020
• Immunoglobulin Light Chains Generate Proinflammatory and Profibrotic Kidney Injury 
  Journal of Clinical Investigation. April 16, 2019

A diagnosis of cancer is life changing for patients and their families. My goal is to help people navigate the challenges of treatment. I greatly enjoy working with a close-knit team where every single player uniquely contributes to the holistic care of every patient.